Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience.
Caputo V, De Falco V, Ventriglia A, Famiglietti V, Martinelli E, Morgillo F, Martini G, Corte CMD, Ciardiello D, Poliero L, De Vita F, Orditura M, Fasano M, Franco R, Caraglia M, Avitabile A, Scalamogna R, Marchi B, Ciardiello F, Troiani T, Napolitano S. Caputo V, et al. Among authors: scalamogna r. Ther Adv Med Oncol. 2022 May 7;14:17588359221096878. doi: 10.1177/17588359221096878. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35547096 Free PMC article.
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients.
Melisi D, Cavaliere A, Gobbo S, Fasoli G, Allegrini V, Simionato F, Gaule M, Casalino S, Pesoni C, Zecchetto C, Merz V, Mambrini A, Barbi E, Girelli R, Giardino A, Frigerio I, Scalamogna R, Avitabile A, Castellani S, Milella M, Butturini G. Melisi D, et al. Among authors: scalamogna r. Pancreatology. 2021 Apr 19:S1424-3903(21)00143-5. doi: 10.1016/j.pan.2021.04.004. Online ahead of print. Pancreatology. 2021. PMID: 33896692
Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors.
Gregorc V, De Braud FG, De Pas TM, Scalamogna R, Citterio G, Milani A, Boselli S, Catania C, Donadoni G, Rossoni G, Ghio D, Spitaleri G, Ammannati C, Colombi S, Caligaris-Cappio F, Lambiase A, Bordignon C. Gregorc V, et al. Among authors: scalamogna r. Clin Cancer Res. 2011 Apr 1;17(7):1964-72. doi: 10.1158/1078-0432.CCR-10-1376. Epub 2011 Feb 9. Clin Cancer Res. 2011. PMID: 21307147 Clinical Trial.
Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.
De Pas T, Rosati G, Spitaleri G, Boni C, Tucci A, Frustaci S, Scalamogna R, Radice D, Boselli S, Toffalorio F, Catania C, Noberasco C, Delmonte A, Vecchio F, de Braud F. De Pas T, et al. Among authors: scalamogna r. Chemotherapy. 2011;57(3):217-24. doi: 10.1159/000326466. Epub 2011 May 18. Chemotherapy. 2011. PMID: 21597285 Clinical Trial.
Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Clavarezza M, Turazza M, Aitini E, Saracchini S, Garrone O, Durando A, De Placido S, Bisagni G, Levaggi A, Bighin C, Restuccia E, Scalamogna R, Galli A, Del Mastro L. Clavarezza M, et al. Among authors: scalamogna r. Breast. 2013 Aug;22(4):470-5. doi: 10.1016/j.breast.2013.03.012. Epub 2013 May 1. Breast. 2013. PMID: 23642526 Clinical Trial.
13 results